Cargando…

Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry

BACKGROUND: Risk models integrating new biomarkers to predict cardiovascular events in acute coronary syndromes (ACS) are lacking. Therefore, we evaluated the prognostic value of biomarkers in addition to clinical predictors and developed a biomarker-based risk model for major adverse cardiovascular...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiali, Gao, Wei, Chen, Guanghui, Chen, Ming, Wan, Zhi, Zheng, Wen, Ma, Jingjing, Pang, Jiaojiao, Wang, Guangmei, Wu, Shuo, Wang, Shuo, Xu, Feng, Chew, Derek P., Chen, Yuguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160492/
https://www.ncbi.nlm.nih.gov/pubmed/35664511
http://dx.doi.org/10.1016/j.lanwpc.2022.100479
_version_ 1784719281057955840
author Wang, Jiali
Gao, Wei
Chen, Guanghui
Chen, Ming
Wan, Zhi
Zheng, Wen
Ma, Jingjing
Pang, Jiaojiao
Wang, Guangmei
Wu, Shuo
Wang, Shuo
Xu, Feng
Chew, Derek P.
Chen, Yuguo
author_facet Wang, Jiali
Gao, Wei
Chen, Guanghui
Chen, Ming
Wan, Zhi
Zheng, Wen
Ma, Jingjing
Pang, Jiaojiao
Wang, Guangmei
Wu, Shuo
Wang, Shuo
Xu, Feng
Chew, Derek P.
Chen, Yuguo
author_sort Wang, Jiali
collection PubMed
description BACKGROUND: Risk models integrating new biomarkers to predict cardiovascular events in acute coronary syndromes (ACS) are lacking. Therefore, we evaluated the prognostic value of biomarkers in addition to clinical predictors and developed a biomarker-based risk model for major adverse cardiovascular events (MACE) within 12 months after hospital admission with ACS. METHODS: Patients (n = 4407) consecutively enrolled from November, 2017 to October, 2019 in three hospitals of a prospective Chinese registry (BIomarker-based Prognostic Assessment for Patients with Stable Angina and Acute Coronary Syndromes, BIPass) were designated as the risk model development cohort. Validation was performed in 1409 patients enrolled in two independent hospitals. Cox proportional hazards regression analysis was used to generate a risk prediction model and evaluate the incremental prognostic value of each biomarker. FINDINGS: Over 12 months, 196 patients experienced MACE (5.1%/year). Among twelve candidate biomarkers, N-terminal pro-B-type natriuretic peptide (NT-proBNP) measured at baseline showed the most prognostic capability independent of clinical predictors. The developed BIPass risk model included age, hypertension, previous myocardial infarction, stroke, Killip class, heart rate, and NT-proBNP. It displayed improved discrimination (C-statistic 0.79, 95% CI 0.73-0.85), calibration (GOF = 9.82, p = 0.28) and clinical decision curve in the validation cohort, outperforming the GRACE and TIMI risk scores. Cumulative rates for MACE demonstrated good separation in the BIPass predicted low, intermediate, and high-risk groups. INTERPRETATION: The BIPass risk model, integrating clinical variables and NT-proBNP, is useful for predicting 12-month MACE in ACS. It effectively identifies a gradient risk of cardiovascular events to aid personalized care. FUNDING: National Key R&D Program of China (2017YFC0908700, 2020YFC0846600), National S&T Fundamental Resources Investigation Project (2018FY100600, 2018FY100602), Taishan Pandeng Scholar Program of Shandong Province (tspd20181220), Taishan Young Scholar Program of Shandong Province (tsqn20161065, tsqn201812129), Youth Top-Talent Project of National Ten Thousand Talents Plan and Qilu Young Scholar Program.
format Online
Article
Text
id pubmed-9160492
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91604922022-06-03 Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry Wang, Jiali Gao, Wei Chen, Guanghui Chen, Ming Wan, Zhi Zheng, Wen Ma, Jingjing Pang, Jiaojiao Wang, Guangmei Wu, Shuo Wang, Shuo Xu, Feng Chew, Derek P. Chen, Yuguo Lancet Reg Health West Pac Articles BACKGROUND: Risk models integrating new biomarkers to predict cardiovascular events in acute coronary syndromes (ACS) are lacking. Therefore, we evaluated the prognostic value of biomarkers in addition to clinical predictors and developed a biomarker-based risk model for major adverse cardiovascular events (MACE) within 12 months after hospital admission with ACS. METHODS: Patients (n = 4407) consecutively enrolled from November, 2017 to October, 2019 in three hospitals of a prospective Chinese registry (BIomarker-based Prognostic Assessment for Patients with Stable Angina and Acute Coronary Syndromes, BIPass) were designated as the risk model development cohort. Validation was performed in 1409 patients enrolled in two independent hospitals. Cox proportional hazards regression analysis was used to generate a risk prediction model and evaluate the incremental prognostic value of each biomarker. FINDINGS: Over 12 months, 196 patients experienced MACE (5.1%/year). Among twelve candidate biomarkers, N-terminal pro-B-type natriuretic peptide (NT-proBNP) measured at baseline showed the most prognostic capability independent of clinical predictors. The developed BIPass risk model included age, hypertension, previous myocardial infarction, stroke, Killip class, heart rate, and NT-proBNP. It displayed improved discrimination (C-statistic 0.79, 95% CI 0.73-0.85), calibration (GOF = 9.82, p = 0.28) and clinical decision curve in the validation cohort, outperforming the GRACE and TIMI risk scores. Cumulative rates for MACE demonstrated good separation in the BIPass predicted low, intermediate, and high-risk groups. INTERPRETATION: The BIPass risk model, integrating clinical variables and NT-proBNP, is useful for predicting 12-month MACE in ACS. It effectively identifies a gradient risk of cardiovascular events to aid personalized care. FUNDING: National Key R&D Program of China (2017YFC0908700, 2020YFC0846600), National S&T Fundamental Resources Investigation Project (2018FY100600, 2018FY100602), Taishan Pandeng Scholar Program of Shandong Province (tspd20181220), Taishan Young Scholar Program of Shandong Province (tsqn20161065, tsqn201812129), Youth Top-Talent Project of National Ten Thousand Talents Plan and Qilu Young Scholar Program. Elsevier 2022-05-30 /pmc/articles/PMC9160492/ /pubmed/35664511 http://dx.doi.org/10.1016/j.lanwpc.2022.100479 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Wang, Jiali
Gao, Wei
Chen, Guanghui
Chen, Ming
Wan, Zhi
Zheng, Wen
Ma, Jingjing
Pang, Jiaojiao
Wang, Guangmei
Wu, Shuo
Wang, Shuo
Xu, Feng
Chew, Derek P.
Chen, Yuguo
Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry
title Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry
title_full Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry
title_fullStr Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry
title_full_unstemmed Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry
title_short Biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – Results from BIPass registry
title_sort biomarker-based risk model to predict cardiovascular events in patients with acute coronary syndromes – results from bipass registry
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160492/
https://www.ncbi.nlm.nih.gov/pubmed/35664511
http://dx.doi.org/10.1016/j.lanwpc.2022.100479
work_keys_str_mv AT wangjiali biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry
AT gaowei biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry
AT chenguanghui biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry
AT chenming biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry
AT wanzhi biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry
AT zhengwen biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry
AT majingjing biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry
AT pangjiaojiao biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry
AT wangguangmei biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry
AT wushuo biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry
AT wangshuo biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry
AT xufeng biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry
AT chewderekp biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry
AT chenyuguo biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry
AT biomarkerbasedriskmodeltopredictcardiovasculareventsinpatientswithacutecoronarysyndromesresultsfrombipassregistry